50 results about "Bladder Tissue" patented technology

Embodiments for an anchor for use in effecting the anastomosis of a patient's bladder and urethra following a prostatectomy are disclosed. The anchor may comprise a shaft with a lodging structure. Alternative embodiments may include a penetration limiting structure, a driver interface proximate to a rearward end, a forward end with a penetration facilitating shape that may comprise a point defined by three flat intersecting faces, a bioabsorbable portion of one or more bioabsorbable materials, and a metal portion of one alloy, or a plurality of alloys which may have differing expansion properties.

A composition for delivering a tumor therapeutic agent to a patient includes a fast-release formulation of a tumor apoptosis inducing agent, a slow-release formulation of a tumor therapeutic agent, and a pharmaceutically acceptable carrier. An apoptosis-inducing agent in a pharmaceutically acceptable carrier may be administered before or concomitantly therewith. Nanoparticles or microparticles (e.g., cross-linked gelatin) of the therapeutic agent (e.g., paclitaxel) also may be used. The nanoparticles or microparticles may be coated with a bioadhesive coating. Microspheres that agglomerate to block the entrance of the lymphatic ducts of the bladder to retard clearance of the microparticles through the lymphatic system also may be employed. This invention also uses drug-loaded gelatin and poly(lactide-co-glycolide) (PLGA) nanoparticles and microparticles to target drug delivery to tumors in the peritoneal cavity, bladder tissues, and kidneys.

Regions of tissue having reduced electrical propagation are created in a bladder to affect its electrical or mechanical properties. To create these tissue regions, a tubular device is advanced through the urethra leading to the interior of the bladder, a distal expandable structure of the device is expanded to contact the inner wall of the bladder, and electrodes or other active energy delivery elements of the device are activated to deliver ablation energy. The electrodes or other active energy delivery elements are disposed over the expandable structure which is shaped to conform to the interior of the bladder. The inner wall of the organ is ablated in a predetermined pattern. The same or other electrodes disposed over the expandable structure can used to electrically map the bladder. This map of electrical activity can be used to create the predetermined pattern.

The present invention discloses a preparation method of a soft tissue decellular matrix, and relates to the technical field of clinical medicine, biomedical medicine and regenerative medicine. According to the present invention, the natural soft tissue decellular matrix is prepared by using a supercritical fluid technology, wherein the natural soft tissue comprises small intestine tissue, blood vessel tissue, muscle tissue, heart tissue, valve tissue, lung tissue, spleen tissue, kidney tissue, liver tissue, stomach tissue, gallbladder tissue, fat tissue, cartilage tissue, trachea tissue, esophagus tissue, bladder tissue, ureter tissue, oviduct tissue, or uterus tissue. According to the present invention, with the preparation method, the damage on the soft tissue matrix component is low, and the obtained soft tissue decellular matrix has advantages of low immunogenicity and good biocompatibility.

The present invention relates to a 3 dimensional mimetic tissue structure—“Assembloid” based on patient-derived multiple cell types to develop next generation organoid technology serving as a novel platform for new drug development and a disease model and a method of manufacturing the same, and more particularly, to a stem cell- or tumor cell-based 3D multicellular mimetic tissue structure manufactured by reconstituting epithelial or tumor cells with various cellular components of a microenvironment such as stromal cells, vascular cells, immune cells or muscle cells based on three-dimensional (3D) bioprinting, and a method of manufacturing the same. As the stem cell- or tumor cell-based 3D multicellular mimetic tissue structure containing the major factors of a tissue microenvironment, such as stromal cells, vascular cells, immune cells and muscle cells, designed according to the present invention is confirmed to mimic physiological and pathological characteristics of tissue in the body better than conventional organoids, normal and tumor assembloids may be used as a new platform for new drug development and a disease model. More specifically, together with 3D bioprinting technology, it is expected that in vitro bladder tissue and bladder tumor tissue are effectively used as a platform to develop precise and personalized therapeutic options for bladder related diseases including bladder cancer.

The invention relates to a method for constructing an air bladder cell system of blotchy rockcod, which comprises: taking an air bladder tissue of the blotchy rockcod as a material to start primary culture, and culturing the air bladder tissue in a DMEM / F12 liquid medium which contains fetal calf serum, carboxymethyl chito-oligosaccharide, basic fibroblast growth factors, I-type insulin-like growth factors, N-acetyl glucose hydrochloride and culture supernatant of heart cells of the blotchy rockcod in the log phase and has a pH value of between 7.0 and 7.4; and adopting a trypsin digestion method for subculturing. The air bladder cell system of the blotchy rockcod constructed by the method is subcultured for 62 generations currently. The technology is scientific and reasonable, is hopeful to be applied to ecotoxicological research, performs pollution monitoring and safety evaluation on various environmental pollutants in the sea, and can also be applied to separation, identification and in vitro breeding of fish viroids, and research in the aspects of interaction of viruses and host cells, and so on.

Tissue compression devices including a multi-chamber bladder that is retained within the tissue compression device, with the multi-chamber bladder being positioned in a bladder orifice in a base of a compression device body. The multi-chamber bladder includes at least one upper chamber located above the base and at least one lower chamber located below the base. The lower chamber is located between the base and a selected location on a patient when the compression device is positioned over selected tissue such as, e.g., a radial artery, as described herein.

The invention relates to an application of DHFR in bladder cancer detection, and belongs to the technical field of molecular biology gene detection. The application includes the following steps: 1, respectively extracting DNA from the bladder tissue and peripheral blood of a sample to obtain DNA templates; 2, respectively carrying out real-time quantitative PCR amplification on the DNA extracted from the bladder tissue and peripheral blood of the sample with a primer pair P as a primer; and 3, calculating the log2 ratio of the sample according to delta delta Ct, and comparing the log2 ratio with copy number variation obtained by using whole genome sequencing data, and determining as a bladder cancer sample when the copy number variation is more than 2.5 or is less than 1.5 or when a G fraction obtained through an GISTIC algorithm is more than 0.08 or is less than 0.08. In the invention, sequence amplified DHFR can be used as a marker for the bladder cancer detection; and DHFR gene can be used as a gene target treatment kit of the bladder cancer.

The invention belongs to the technical field of biological medicine, and discloses a bladder targeted drug-loaded exosome and application as well as a drug for treating bladder diseases. The drug for treating bladder diseases is introduced into the exosome with bladder tissue targeting property to obtain the exosome, and the exosome with bladder tissue targeting property is derived from kidney cells; and a bladder tumor treatment drug contains the bladder targeted drug-loaded exosome. Compared with the prior art, the exosome secreted by the kidney cells can be enriched in the bladder tissue without any modification, the exosome derived from the kidney cells is used, the problem of exosome yield is solved, and the application prospect is very good; and the exosome from the kidney cells can be used for loading different drugs or active molecules, through targeted bladder tissue administration, the treatment effect on bladder diseases is improved, and toxic and side effects of the drugs are reduced.

The invention discloses a side balloon urinary catheter for preventing clogging and preventing urine leakage. The side balloon urinary catheter includes a second connection seat, a flow guiding tube,a first connection seat, a first catheter, a telescopic tendon body, a balloon bag, a second catheter, a balloon, a urinary catheterization port and an end cap. According to the side balloon urinary catheter, a balloon ball tightly adheres to bladder tissue by injecting water into the balloon, the effect of squeezing urine out of a urination port is achieved by controlling the internal pressure ofthe bladder; a method of arranging the balloon bag and the telescoping tendon body is adopted, the balloon bag is expanded through a method of injecting water or air into the balloon bag, the telescoping tendon body is expanded, and the telescoping tendon body is close to urethra of a patient, the effect that urine is prevented from flowing between the urethra and the outer wall of the catheter is achieved, the telescopic tendon body avoids the problems of over-expansion and uneven expansion of the balloon bag, and the side balloon urinary catheter has the characteristics that operation is simple, the patient has less pain, and lateral flow of urine is prevented.

The present invention provides methods for imaging and the treatment of cancer. In certain embodiments, a polyarginine (e.g., R11) may be used to selectively image prostate or bladder cells (e.g., a metastatic prostate cancer). In other embodiments, a DOC-2 / DAB2 peptide, optionally conjugated to a cell permeable peptide (e.g., R11) may be used to treat a cancer, such as prostate cancer.

A vapor delivery system and method is provided that is adapted for ablating bladder tissue to treat overactive bladder (OAB). The vapor delivery system includes an anchor tip configured anchor the system in the bladder while condensable vapor is delivered to target tissue. In one method, the vapor delivery system is advanced transurethrally into the patient to access the target tissue of the bladder, which can include a surface sensor of the bladder responsible for creating an urge incontinence sensation. The vapor delivery system includes a vapor source that provides a high quality vapor for delivery to tissue.

Methods, devices, and medicaments that include trospium are provided for use in the treatment of bladder dysfunction by locally administering the trospium into the bladder to achieve a sustained concentration of trospium in urine in the bladder sufficient to produce a therapeutic concentration of trospium in bladder tissue. The drug may be delivered into the bladder from an intravesical drug delivery device inserted into the bladder, wherein the device continuously releases the drug into the urine in the bladder over an extended period of hours or days.

The invention relates to a back-suction preventive bladder irrigator, comprising an irrigating tube, an irrigating liquid balloon and a rubber balloon. The rubber balloon is provided with protrusions formed integrally with the rubber balloon. The rubber balloon is provided with a rubber connecting tube. The irrigating liquid balloon is provided with a first connecting tube and a second connecting tube. The first connecting tube is connected with the irrigating tube. One end of the irrigating tube is connected with a silicone valve, and the other end thereof is connected with an irrigating connector. The silicone valve is funnel shaped, a large end face of the silicone valve is connected with the irrigating tube, and a small end face of the silicone valve is disposed in the first connecting tube. The silicone valve is composed of a valve flap which is provided with a strainer. The strainer is inwardly concave or outwardly convex. The back-suction preventive bladder irrigator has the advantages that the cost is low, the irrigator is handy, disposable and tolerant to high-temperature sterilizing and is suitable for fully irrigating the bladder, prostate or bladder tissues are avoided being sucked back into the bladder, the surgical time is shortened, surgical risk is decreased, and the irrigator has a promising clinical application prospect.

Provided herein are urine progenitor cells and methods for producing a culture of urine progenitor cells from a urine sample. The cells may be selected based upon the use of a selective cell medium, based upon morphology, and / or by selecting cell-specific markers. Also provided is an isolated urine progenitor cell that is c-kit positive and can differentiate into urothelium, smooth muscle, endothelium or interstitial cells. Methods of use of urine progenitor cells are provided, wherein cell are seeded onto a tissue scaffold are provided. Methods of treating a subject in need thereof are also provided, including providing a bladder tissue substrate that includes differentiated UPCs and transplanting the substrate into the patient. Finally, kits are provided that include a container suitable for the transport of a urine sample; media; one or more antibiotics; a package for holding said container, media, and antibiotics; and optionally, instructions for use.